*Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm Newsfile Corp
Market data is delayed by at least 15 minutes.
    Latest Story Top Stories on ZNTL
    Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm
    10:49a ET May 3 '24 Newsfile Corp

    New York, New York--(Newsfile Corp. - May 3, 2024) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.

    If you own ZNTL please contact Justin Kuehn, Esq. by email at justin@kuehn.law or call (833) 672-0814. The consultation and case are free with no obligation to you. Kuehn Law pays all case costs and does not charge its investor clients.Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

    Why Your Participation Matters:

    As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™

    For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.

    Attorney advertising. Prior results do not guarantee similar outcomes.

    Contacts:Kuehn Law, PLLCJustin Kuehn, Esq.53 Hill Street, Suite 605Southampton, NY 11968justin@kuehn.law(833) 672-0814

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/207889

    COMTEX_451835973/2523/2024-05-03T10:49:11

    Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Lis...
    5:30p ET May 1 '24 GlobeNewswire
    Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating ...
    4:05p ET April 2 '24 GlobeNewswire
    Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Lis...
    5:30p ET April 1 '24 GlobeNewswire
    Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Lis...
    6:00p ET March 1 '24 GlobeNewswire
    Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferen...
    7:00a ET February 28 '24 GlobeNewswire
    Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and...
    7:00a ET February 27 '24 GlobeNewswire
    Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare...
    7:00a ET February 13 '24 GlobeNewswire

    Market data provided by News provided by